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ment of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USAIntroduction: Primary membranous nephropathy (MN) is characterized by the presence of antipodocyte anti-
bodies, but studies describing phenotypic and functional abnormalities in circulating lymphocytes are limited.
Methods: We analyzed 68 different B- and T-cell subsets using flow cytometry in 30 MN patients (before
initiating immunosuppression) compared with 31 patients with non–immune-mediated chronic kidney dis-
ease (CKD) and 12 healthy individuals. We also measured 19 serum cytokines in MN patients and in healthy
controls. Lastly, we quantified the ex vivo production of phospholipase A2 receptor (PLA2R)-specific IgG by
plasmablasts (measuring antibodies in culture supernatants and by the newly developed FluoroSpot assay
[AutoImmun Diagnostika, Strasberg, Germany]) and assessed the circulating antibody repertoire by phage
immunoprecipitation sequencing (PhIP-Seq).
Results: After adjusting for multiple testing, plasma cells and regulatory B cells (BREG) were significantly
higher (P < 0.05) in MN patients compared with both control groups. The percentages of circulating plasma
cells correlated with serum anti-PLA2R antibody levels (P ¼ 0.042) and were associated with disease activity.
Ex vivo–expanded PLA2R-specific IgG-producing plasmablasts generated from circulating PLA2R-specific
memory B cells (mBCs) correlated with serum anti-PLA2R IgG antibodies (P < 0.001) in MN patients. Tu-
mor necrosis factor-a (TNF-a) was the only significantly increased cytokine in MN patients (P < 0.05), whereas
there was no significant difference across study groups in the autoantibody and antiviral antibody repertoire.
Conclusion: This extensive phenotypic and functional immune characterization shows that autoreactive
plasma cells are present in the circulation of MN patients, providing a new therapeutic target and a
candidate biomarker of disease activity.
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rimary MN is an autoantibody-mediated glomer-
ular disease that represents one of the leading
causes of nephrotic syndrome in adults.1 MN autoanti-
bodies are typically IgG that target podocyte antigens
and deposit on the subepithelial layer of the glomerular
capillary wall.2 MN kidneys show thickened glomer-
ular basement membranes, complement activation,3–5Kidney International Reports (2020) 5, 1764–1776
C Cantarelli et al.: Diabetic Nephropathy TRANSLATIONAL RESEARCHand glomerular capillary injury, leading to significant
nephrotic-range proteinuria.6,7 About one-third of pa-
tients experience spontaneous remission, another third
progress to end-stage renal failure, and the remaining
third have persistent proteinuria with slower decline
to end-stage renal failure.8–11
Considerable advances have been made in the un-
derstanding of the pathophysiology of MN with the
identification of autoantibodies targeting phospholi-
pase A2 receptor in approximately 60% to 70% of MN
patients.12–15 In contrast with autoantibodies, circu-
lating lymphocyte populations have been less thor-
oughly investigated in MN. Some investigators
reported an increased CD4þ/CD8þ T-cell ratio in MN
patients with or without nephrotic proteinuria,16,17
which has been attributed to a reduction in CD8þ T
cells.18 In 2017, Rosenzwajg et al.19 measured 33
lymphocyte subpopulations in 25 MN patients and 27
healthy subjects and found that MN patients had
significantly lower regulatory T cells (TREG) compared
with healthy controls.19 MN patients who responded to
B-cell depleting therapy showed a significantly
increased percentage of TREG than nonresponders. The
same study19 showed that, consistent with previous
reports on other autoimmune diseases,20,21 MN patients
have an increased frequency of circulating naive B
cells, whereas switched and nonswitched mBCs are
decreased. This finding, together with the clinical ef-
ficacy of B-cell depleting therapies, has highlighted the
central pathogenic role of B lymphocytes in MN.
However, functional studies to assess the presence of
circulating B cells reactive against PLA2R antigen have
not yet been performed. Moreover, studies published
so far are limited by the low number of B- and T-cell
subsets analyzed, as well as by the lack of control
subjects with CKD, which prevented the dissection of
immune phenotypic abnormalities that may be common
to all patients with renal insufficiency of any etiology.
To address these issues, we performed a detailed
phenotypic and functional analysis of circulating B-
and T-cell populations in patients with MN and in CKD
and healthy controls to pinpoint the subsets that best
identify the immune phenotypic abnormalities char-
acteristic of MN.METHODS
Study Population
We included patients with new-onset MN enrolled at 2
centers: S. Orsola-Malpighi Hospital, University of
Bologna, Bologna, Italy (n ¼ 16), and Complejo Hospi-
talario de Navarra, Pamplona, Spain (Biobank Nav-
arrabiomed, n ¼ 14 [integrated in the Spanish National
Biobanks Network]). Patients with MN were diagnosedKidney International Reports (2020) 5, 1764–1776using the standard criteria set by the World Health
Organization.22 Exclusion criteria were secondary
types of MN, such as lupus nephritis, Henoch-
Schonlein purpura, hepatitis B virus– or hepatitis C
virus–associated MN, neoplasia, pregnancy, concomi-
tant other autoimmune diseases or other infections, and
the use of immunosuppressive therapy. Primary (n ¼ 7)
and secondary (n ¼ 2) MN patients used for the
functional ex vivo assays were enrolled at Bellvitge
University Hospital, Barcelona, Spain. All individuals
were enrolled from November 2017 to June 2019. The
definitions of clinical outcomes and the methods for
autoantibodies targeting phospholipase A2 receptor
measurement are reported in Supplementary
Appendix.
As controls for immunophenotyping, we included
patients with non–immune-mediated CKD (diabetic
nephropathy, n ¼ 9; chronic hypertensive nephropa-
thy, n ¼ 8; autosomal dominant polycystic kidney
disease, n ¼ 5; and unspecified CKD, n ¼ 9). For PhIP-
Seq, we used sera from the same patients included in
the immune phenotyping studies and additional sera
from 3 MN and 22 CKD patients. We also included sex-
and age-matched healthy subjects with no known
autoimmune or inflammatory diseases.
Samples and data from patients included in this
study were processed following standard operating
procedures with the appropriate approval of the ethics
and scientific Committees of the 3 institutions.Flow Cytometry Analysis
Peripheral blood mononuclear cells were isolated from
peripheral blood by Ficoll gradient and stored in liquid
nitrogen for batched analysis. We designed 7 multi-
color flow cytometry panels to quantify 68 cell subsets
and to calculate the CD4þ/CD8þ T-cell ratio
(Supplementary Table S1). The following
fluorochrome-conjugated antihuman antibodies were
used from BD Biosciences (Franklin Lakes, NJ): CD3-
FITC, CD3-PerCP-Cy5.5, CD4-APC-Cy7, CD8-BV510,
CD45RO-FITC, CD45RA-APC, CD45RA-APC-H7, CD71-
PE, IgD-PerCP-Cy5.5, CD25-APC-Cy7, CD138-BV421,
CCR4-PE, CD27-PE, CD95-BV421, CD28-BV421, CCR6-
BV421, CXCR3-PE, IL-4-PE, and IFN-g-PE-Cy7. From
Biolegend (San Diego, CA), the following were used:
CD19-BV510, CD56-FITC, CD27-APC, CD127-FITC,
CD57-PerCp-Cy5.5, PD-1-APC-Cy7, and CXCR5-FITC,
and from eBioscience (San Diego, CA), the following
were used: CD4-PE-Cy7, CD21-PE, and CD24-APC-Cy7.
From Miltenyi Biotec (Bergisch Gladbach, German),
CD25-APC and KLRG1-PE were used; from Beckman
Coulter (Brea, CA), CD38-PE-Cy7 was used; and from
Invitrogen (Carlsbad, CA), IL-17-APC was used. Isotype1765
TRANSLATIONAL RESEARCH C Cantarelli et al.: Plasma Cells in Membranous Nephropathycontrols IgG1,k-FITC, IgG1,k-PE, and IgG2b,k-APC
(BD Biosciences) were used for gate placement.
Intracellular staining for interleukin (IL)-17, IL-4,
and interferon-g was performed with extracellular
markers for CD4þ, CD8þ, and CD19þ. Cells were fixed
and permeabilized using Intracellular Fixation and
Permeabilization Buffer Set (eBioscience) according to
the manufacturer’s instructions. Data were acquired
(>1  106 events) on a 3-laser FACSLyric flow cy-
tometer (BD Biosciences) and analyzed with FlowJo
software (BD Life Sciences; Franklin Lakes, NJ).
Cytokine/Chemokine
We quantified plasma levels of CD40L, granulocyte
colony-stimulating factor/colony-stimulating factor 3,
granulocyte-macrophage colony-stimulating factor,
interferon-g, IL-1b, IL-10, IL-12p70, IL-13, IL-17A,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, monocyte
chemoattractant protein-1, macrophage inflammatory
protein-1b, TNF-a, and tumor necrosis factor-b in a
subset of 19 MN patients and 8 healthy controls using
xMAP Technology (Luminex, Austin, TX). Serum
samples were not available for CKD controls. We
created a multiplex panel combining 2 commercially
available simplex kits: Human Custom Procarta Plex-19
plex (Cat. No. PPX-19-MXRWE2G; Invitrogen by
Thermo Fisher Scientific, Waltham, MA) and Human
High Sensitivity T Cell (Cat. No. HSTCMAG-28SK;
Merck Millipore, Burlington, MA). The methodolog-
ical details including assay protocol, standards, and
sensitivity are available at the manufacturers’ websites
(http://www.thermofisher.com and http://www.
merckmillipore.com, respectively). All samples were
measured undiluted and in duplicates. The chemo/
cytokine standards were assayed in the same way as
patient samples. The data were collected using xPO-
NENT software (Luminex).
Functional Assessment of Circulating
PLA2R-Specific IgG-Producing Plasmablasts
Quantification of PLA2R-Specific IgG by Polyclonally
Expanded Plasmablasts
The induction and differentiation of circulating mBCs
into antibody-secreting plasmablasts were performed
as previously described.23–25 Briefly, peripheral blood
mononuclear cells were resuspended at 1.5  106 cells/
ml concentration in Iscove’s modified Dulbecco’s me-
dium (Gibco Invitrogen, Paisley, UK) containing 10%
fetal bovine serum (Hyclone, Gibco) supplemented
with 2 mmol/l L-glutamine (Gibco Invitrogen), 100 U/
ml penicillin, and 100 mg/ml streptomycin (Gibco
Invitrogen). Cells were activated for 6 days with
500 ng/ml a-CD40 mAb (R&D Systems, Minneapolis,
MN), 2.5 mg/ml toll-like receptor-9 ligand1766oligodeoxynucleotides 2006 CpG (Hycult Biotech-
nology, Uden, the Netherlands), 600 IU/ml IL-2 (Sigma-
Aldrich, St. Louis, MO), 25 ng/ml IL-10 (R&D Systems),
and 100 ng/ml IL-21 (Gibco Invitrogen). Such poly-
clonal stimulation results in the appearance of an IgG
antibody secreting cell–like population with a
CD19þCD20lowCD27þCD38highIgD phenotype that has
been previously shown to arise from circulating mBCs
preserving their original B-cell repertoire.24 Superna-
tants of these 6-day polyclonally stimulated mBCs were
screened for anti–PLA2R-specific IgG antibodies using
single-antigen flow bead assays on a customized
Luminex platform (OriGene Technologies, Rockville,
MD). The mean fluorescence intensity threshold for
Luminex positivity was 500.
B-Cell FluoroSpot Assay to Track Circulating
Frequencies of PLA2R-Specific IgG-Producing
Plasmablasts
To test the frequencies of those PLA2R-specific mBCs
capable of switching into a plasmablast-like phenotype
producing PLA2R (IgG)-specific antibodies in vitro, we
evaluated them in a new B-cell enzyme-linked immu-
nosorbent FluoroSpot assay. Briefly, FluoroSpot plates
were coated with a monoclonal antibody against human
IgG and blocked to avoid unspecific interactions. Pe-
ripheral blood mononuclear cells were stimulated as
specified earlier and seeded into FluoroSpot plates and
incubated to release IgG. The total polyclonal IgG wells
were used as positive controls to confirm cell viability
for each subject per stimulation.
IgG antibody secreting cells were detected with anti-
human IgG conjugated with alkaline phosphatase, and
PLA2R-specific IgG antibody secreting cells were
detected using fluorescent dye–labeled multimerized
PLA2R monomers.
PhIP-Seq to Screen for Autoantibodies
PhIP-Seq was performed using a slightly modified
version of previously published PhIP-Seq pro-
tocols.26,27 Briefly, we used a human proteome phage
display library consisting of 259,345 overlapping 90-aa
peptide sequences (human90 library28 and a human
virome phage display library consisting of 93,904
overlapping 56-aa peptide sequences [VirScan li-
brary]).29 The IgG concentration of each plasma sample
was determined using an in-house IgG enzyme-linked
immunosorbent assay using capture and detection an-
tibodies from Southern Biotech, Birmingham, AL (Cat.
No. 2040-01 and Cat. No. 2042-05). Immunoprecipita-
tion reactions occurred in 1-ml mixture containing
plasma (2 mg IgG), 2.6  1010 plaque-forming units of
the human peptidome library, and 0.94  1010 plaque-
forming units of the virome library diluted in PBS.
After rotating the reaction mix overnight at 4 C, 20 mlKidney International Reports (2020) 5, 1764–1776
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(Cat. No. 10002D and Cat. No.10004D, Invitrogen) were
added to each reaction and rotated for 4 hours at 4 C.
The beads were washed 3 times using a 96-well mag-
netic stand, followed by resuspension of the beads in
20 ml of a polymerase chain reaction master mix con-
taining Q5 polymerase (Cat. No. M0492L; New England
BioLabs, Ipswich, MA). After 15 cycles of polymerase
chain reaction, 2 ml of the polymerase chain reaction
reaction was added to a second 20 cycle polymerase
chain reaction for the addition of sample bar codes and
P5/P7 Illumina adapters (Illumina, San Diego, CA).
Sequencing was performed on an Illumina NextSeq 500
system (high output, single end, 75 bp) using custom
sequencing primers. See Supplementary Appendix for
information on data analyses.
Statistical Analysis
Of the original 68 cell subsets, we dropped 11 of them
because they were missing in over 10% of the patients
(in 10 of them, they were missing in over 50% of the
subjects). Among the remaining 57 cell subsets, based
on the degree of redundancy evaluated by statistical
collinearity and correlation as well as by background
knowledge, we eventually selected 30 cell subsets
(Supplementary Table S1) for the main analyses and 52
cell subsets for sensitivity analyses (Supplementary
Appendix and Supplementary Figure S1).
Among the 30 cell subsets, we used the Kruskal-
Wallis joint test to identify those that were statisti-
cally significant across MN, CKD, and health controls.
P values were adjusted for multiple testing using the
Holm-Bonferroni procedure.30 Among the jointly sig-
nificant subsets, we identified those that were also
statistically significant in both pair-wise comparisons
(i.e., between MN and CKD and between MN and
healthy controls) using a Mann-Whitney 2-sample, 2-
tailed test with a significant level of 0.025. For sensi-
tivity analysis, we used random forest analysis,31
which consists in constructing a multitude of classifi-
cation trees, each based on a random sample of the
variables used for classification, and then summarizing
which variables proved to be most useful in dis-
tinguishing between groups by ranking them accord-
ing to variable importance. In contrast to pair-wise
statistical testing (used previously), the random forest
analysis accounts for the fact that different cell subsets
may jointly help distinguishing MN from the other
groups. Therefore, this approach accounts for possible
interactions between different cell subsets (i.e.,
possible synergic effects of 2 different cell subsets in
improving classification between MN and the other 2
groups). Further details of the additional statistical
analyses (e.g., least absolute shrinkage and selectionKidney International Reports (2020) 5, 1764–1776operator for variables from the 52 cell subsets) are re-
ported in Supplementary Appendix. Random forest
analysis and least absolute shrinkage and selection
operator were not used for the purpose of building a
prediction model but rather as a sensitivity analysis of
cell subset selection because these methods may better
handle nonlinear relations and interactions between
cell subsets (random forest) and highly correlated
covariates (least absolute shrinkage and selection
operator).
In order to report findings that could easily be
compared with future studies, we calculated nonpara-
metric bootstrap 95% confidence intervals of the me-
dian and lower and upper quartiles of each significant
cell subset for each of the 3 groups.32
As a final verification of our findings, we examined
the linear relation between the selected cell subsets and
anti-PLA2R antibody levels in MN patients in whom
the titer was available and positive. To this purpose,
we used gamma regression via generalized linear
models due to the non-normal distribution with long
right tails of anti-PLA2R antibody titer; the P value
was estimated with the nonparametric Monte Carlo 2-
sided permutation test.32 Gamma regression was also
used to fit the relation between supernatant and serum
mean fluorescence intensity.
We compared cytokine levels between patients with
MN and healthy controls using the 2-sample Mann-
Whitney test. A 2-tailed P value < 0.05 after ac-
counting for multiple testing according to the Bonfer-
roni method was regarded as statistically significant
unless otherwise specified. All of the analyses were
performed using Stata release 16.0 (StataCorp LLC,
College Station, TX) and random forest using the R
package randomForest (R version 3.6.2; R Core Team,
Vienna, Austria).
RESULTS
Patients and Control Characteristics
For flow cytometric analyses, we included 30 patients
with MN, 31 patients with other non–immune-medi-
ated CKDs, and 12 healthy controls (Table 1). MN pa-
tients had severe proteinuria and slightly impaired
renal function. Consistent with the available litera-
ture,12,33 over 60% of them were positive for anti-
PLA2R antibodies. Sex and age were similar across
the 3 study groups (Table 1).
Circulating Plasma Cells and BREG Are
Selectively Increased in MN Patients
We started by identifying the B- and T-cell subsets
that, among the 68 that we tested, were significant in
pair-wise comparisons between MN and both CKD and
healthy controls (Supplementary Table S1).1767
Table 1. Characteristics of patients included in flow cytometric
analyses
MN (n [ 30) CKD (n [ 31) HCs (n [ 12) P Value
Male (%) 63.3 74.2 41.7 0.25
Age (years) 59.5  15.9 58.3  16.7 57.0  8.4 0.57
Serum creatinine (mg/dl) 1.2  0.9 3.3  1.5 NA <0.001
Serum albumin (g/dl) 3.0  0.8 4.1  0.5 NA <0.001
Proteinuria (g/24 h) 4.9  3.8 0.86  0.9 NA <0.001
Anti-PLA2R Ab pos (%)a 60.0 NA NA
Anti-PLA2R Ab, autoantibodies targeting phospholipase A2 receptor; CKD, chronic
kidney disease; HCs, healthy controls; MN, membranous nephropathy; NA, not
available.
Categoric variates were compared by the Fisher’s exact test and continuous variates by
the Kruskal-Wallis or Mann-Whitney test.
aFour patients had no anti-PLA2R Ab measured.
TRANSLATIONAL RESEARCH C Cantarelli et al.: Plasma Cells in Membranous NephropathyIn the unadjusted analyses, we found that 17 cell
subsets were significantly different between MN and
HC, but, in most of the cases, MN and CKD patients had
similar values, suggesting that such differences were
not characteristic of MN patients. After adjusting for
multiple testing, we found that only the percentages of
plasma cells and BREG differed significantly in MN
patients compared with both control groups (Figure 1a
and b). There was no statistically significant differenceFigure 1. Plasma cells and regulatory B cells (BREG) in membranous nephro
cells (top) and BREG (bottom) in MN, chronic kidney disease (CKD), and he
and BREG percentages in MN, CKD patients, and HCs. P < 0.025 significant
multiple testing (Holm-Bonferroni procedure).
1768between the 8 anti-PLA2R negative and the 18 positive
MN patients concerning B and plasma cells (P ¼ 0.20).
Next, we used random forest analysis to rank the cell
subsets that best differed MN patients from control groups
(see Statistical Analysis section and Supplementary
Appendix). This analysis confirmed that plasma cells
and, to a lower extent, BREG stood out in distinguishing
patients with MN (Supplementary Figure S2). More in
general, results from random forest analyses indicate that
cell subsets of B-cell lineage overall distinguish MN pa-
tients from both control groups. Additional sensitivity
analyses by least absolute shrinkage and selection operator
(Supplementary Figure S3) converged to identify plasma
cells as the most relevant subset to differentiate MN pa-
tients from the other groups.
We also found a significant association between
the percentage of circulating plasma cells and anti-
PLA2R IgG levels in the subset of autoantibodies
targeting phospholipase A2 receptor–positive patients
(Figure 2).
The percentages of exhausted CD4þ T cells and
TREG were significantly lower in MN patients than inpathy (MN) and control subjects. (a) Representative plots for plasma
althy control (HC) individuals. (b) Boxplots showing the plasma cells
pair-wise differences (MN vs. CKD and MN vs. HC) after adjusting for
Kidney International Reports (2020) 5, 1764–1776
Figure 2. The relation between the percentage of plasma cells and serum anti–phospholipase A2 receptor (anti-PLA2R) IgG titer in membranous
nephropathy patients with detectable anti-PLA2R antibodies. The line represents the fitted line via the gamma regression mode and the shaded
area the 95% confidence interval of the line. The relation was statistically significant (P ¼ 0.042) by the permutation test. Plasma cells are
defined as CD3-CD56-CD19þCD38þhighCD27þhighCD138þ cells.
C Cantarelli et al.: Diabetic Nephropathy TRANSLATIONAL RESEARCHCKD patients and healthy controls, respectively,
whereas naive CD4þ T cells were significantly higher
than in CKD only (Figure 3). Follicular helper T cells
did not significantly differ across the 3 groups.
Similarly, intracellular expression of IFN-g, IL-4, and
IL-17 in CD4þ and CD8þ T cells was not significantly
different across the 3 groups (Supplementary
Figure S4). Overall, these data indicate that plasmaFigure 3. CD4þ T-cell subsets in membranous nephropathy (MN) patients a
T cells, 2 exhausted PD1þCD57CD4þ T-cell subsets, and CCR4þCD45RA
and healthy controls (HCs). P < 0.025 significant pair-wise differences (M
Bonferroni procedure).
Kidney International Reports (2020) 5, 1764–1776cells are the lymphocyte subset that best character-
izes MN patients.
MN Patients Have Increased Circulating Levels
of TNF-a
We assayed a panel of 19 cytokines and chemokines in
the sera of 19 MN patients and 8 healthy controls. Most
cytokines and chemokines were not detectable in thend controls. Boxplots showing CD45RAþCD45ROCD27þ naive CD4þ
-CD25þCD127low TREG in MN, chronic kidney disease (CKD) patients,
N vs. CKD and MN vs. HC) after adjusting for multiple testing (Holm-
1769











#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12
Age (years) 37 38 68 28 69 48 63 76 77 25 52 32
Gender Male Male Male Male Male Male Male Male Male Female Male Female
Months after diagnosis 0 0 0 0 15 96 132 12 60 0 0 0
Plasma albumin (g/dl) 1.9 1.6 2.0 2.3 2.3 4.2 4.4 3.7 3.1 4.2 4.1 3.9
Proteinuria (g/24 h) 5.6 10 13.7 5.27 2.07 2.81 1 14.9 8.02 0 0 0
Serum creatinine (mg/dl) 1.34 2.18 1.35 1.11 6.58 1.64 1.09 2.01 2.11 1.02 0.90 0.97
Immunosuppression - - - - Tac Tac - - - - - -
Serum anti-PLA2R Ab
ELISA (semiquantitive) þ þ þþ þ þþ þþ þþ - - - - -
Luminex (MFI) 9471 8307 8034 4699 16,170 12588 11,005 125 180 75 83 32
Supernatant anti-PLA22R Ab
PLA2R-specific mBc (MFI) 1601 8209 5068 1614 9765 8883 364 274 195 60 17 59
Polyclonal mBc Ab production 132 67 96 143 49 129 39 165 52 79 53 90
Anti-PLA2R Ab, autoantibodies targeting phospholipase A2 receptor; ELISA, enzyme-linked immunosorbent assay; HC, healthy control; mBC, memory B cell; MN, membranous ne-
phropathy; Tac, tacrolimus.
ELISA results: -, þ, and þþ correspond to <20 IU/l, 20 to 150 IU/l, and >150 IU/l, respectively.
All patients were negative for antithrombospondin antibodies.
TRANSLATIONAL RESEARCH C Cantarelli et al.: Plasma Cells in Membranous Nephropathycirculation (Supplementary Table S2). Among the
detectable ones, the only one that was significantly
different between MN patients and healthy controls
was TNF-a) (Supplementary Figure S5), which is
implicated in plasma cell expansion and survival.34
MN Patients Have Autoreactive PLA2R-Specific
IgG-Producing Plasmablasts in the Circulation
Based on these findings, we decided to focus our
studies on plasma cells because they resulted as the cell
subset that best characterizes patients with MN
(Supplementary Figure S2). Although BREG were also
increased in these patients, we reasoned that their in-
crease was compensatory and not primarily pathogenic.
Therefore, we asked whether circulating autoreactive
PLA2R-specific mBCs from MN patients are capable of
switching to PLA2R-specific IgG-producing plasma
blasts (plasma cell precursors). To address this ques-
tion, we measured PLA2R-specific IgG antibodies in the
supernatants of polyclonally expanded memory B cells
obtained from the circulation of 7 MN patients with
serum autoantibodies targeting phospholipase A2 re-
ceptor, 2 patients with secondary MN, and 3 healthy
controls.23–25 PLA2R-positive MN patients showed
PLA2R-specific IgG antibody–producing plasmablasts
in peripheral blood (Table 2). Interestingly, the levels
of ex vivo–produced anti-PLA2R IgG were significantly
correlated with the relative serum levels of autoanti-
bodies (both measured by highly sensitive Luminex
technology), suggesting that the autoreactive plasma-
blast pool is contributing to the overall production of
autoantibodies (Figure 4a). One patient showing clinical
remission after tacrolimus therapy displayed low levels
of anti-PLA2R antibodies in the serum and no anti–
PLA2R-specific IgG in the supernatants, possibly1770suggesting therapy-induced inhibition of autoreactive
plasmablasts. None of the patients with secondary MN
nor the healthy controls showed serum anti-PLA2R
antibodies or anti–PLA2R-IgG–producing plasma-
blasts in the circulation (Figure 4a).
We next aimed to quantify in a functional manner
the frequencies of circulating anti–PLA2R-specific
IgG-producing plasmablasts in 2 representative MN
patients with detectable autoantibodies targeting
phospholipase A2 receptor to further demonstrate the
capacity of this PLA2R-specific cell subset population
to produce autoantibodies. To this purpose, we used
a novel FluoroSpot platform24 that enables determi-
nation of the numbers of plasmablasts secreting
PLA2R-targeted IgG over the global IgG-secreting
plasma cell repertoire. We detected distinct PLA2R-
specific IgG-producing plasma cells only in patients
with anti–PLA2R-specific antibodies, whereas such
cells were not detectable in the circulation of HCs
(Figure 4b). In sum, increased circulating plasma-
blasts in MN patients are, at least in part,
autoreactive.
No Difference in the Circulating Antibody
Repertoires of MN, CKD, and Healthy Control
Subjects
Because MN patients have increased levels of total
circulating plasma cells, we tested whether there is any
abnormality in the antibody repertoire overall. We
performed PhIP-seq on serum IgG from an expanded
cohort including 33 MN patients, 53 CKD patients, and
10 healthy controls. The PhIP-seq assay combines
phage display of a library of peptides with next-
generation sequencing to probe for responses against
many possible epitopes simultaneously, with the keyKidney International Reports (2020) 5, 1764–1776
Figure 4. Ex vivo production of serum anti–phospholipase A2 receptor (anti-PLA2R) IgG by circulating plasmablasts from membranous ne-
phropathy (MN) patients. (a) Association between anti–PLA2R-specific antibodies assessed in plasmablast cell culture supernatants and serum
anti–PLA2R-specific IgG in patients with primary MN at different stages of disease activity, in patients with secondary MN, and in healthy
controls. P < 0.001 by regression analysis. (b) PLA2R B-cell FluoroSpot, anti–PLA2R-specific antibodies in sera (mean fluorescent intensity
[MFI]), and anti-PLA2R-specific antibodies in plasmablast cell culture supernatant (MFI) in 2 patients with MN and clinical flare and 2 healthy
controls.
C Cantarelli et al.: Diabetic Nephropathy TRANSLATIONAL RESEARCHlimitation that it can detect only responses against
linear, rather than conformational, epitopes. We
included a library of 259,345 overlapping 90-mer
peptide sequences covering the human proteome (hu-
man90 library),26 as well as a library containing 93,904
overlapping 56-mer peptides from human-tropic vi-
ruses (VirScan library).29
We did not find significant differences in the
overall number of detected antibody specificitiesKidney International Reports (2020) 5, 1764–1776(hits) between MN patients, CKD patients, and
healthy controls (Figure 5a). However, we noted a
trend toward increased autoantibody hits for MN
patients, with a median of 127 hits per MN patient
compared with 64 for CKD patients and 85 for
healthy controls (t test, P ¼ 0.08). The number of
viral hits was very similar between the groups (me-
dian of 468 for MN patients, 471 for CKD patients,
and 461 for healthy controls).1771
Figure 5. Phage immunoprecipitation sequencing (PhIP-Seq) analysis of circulating antibody repertoire. (a) Total detected antibody specificities
(hits) per serum sample for PhIP-Seq libraries targeting the human proteome (human90 library) and human-tropic viruses (VirScan library).
Differences between groups were assessed using a t test. (b) T-distributed stochastic neighbor embedding (t-SNE) visualization of the overlap
in PhIP-Seq hits between samples. Samples with more hits in common are positioned closer together in this visualization.
TRANSLATIONAL RESEARCH C Cantarelli et al.: Plasma Cells in Membranous NephropathyNo individual epitopes, genes, or viral taxa showed a
significant enrichment in MN versus CKD or healthy
control individuals after correction for multiple hy-
pothesis testing (Supplementary Table S3). This
included antibodies against PLA2R, which were not
identified as PhIP-seq hits in any samples, likely due to
the linear epitope limitation. To assess the overall
clustering of the samples, we visualized the level of
similarity between the hits for each pair of samples
using a t-distributed stochastic neighbor embedding
plot (Figure 5b). This did not indicate any clear clus-
tering of MN, CKD, or healthy control individuals.
Altogether, these data suggest that the self- and1772viral-directed serum antibody repertoires among MN,
CKD, and healthy control individuals are broadly
similar, but a note of caution is recommended in the
consideration of the relatively small cohort size and
PhIP-Seq limitations.DISCUSSION
The present study shows that MN patients display
significantly higher percentages of circulating plasma
cells and BREG than patients with non–immune-medi-
ated CKD and healthy controls. Further analyses sup-
port the concept that a fraction of these circulatingKidney International Reports (2020) 5, 1764–1776
C Cantarelli et al.: Diabetic Nephropathy TRANSLATIONAL RESEARCHplasma cells are autoreactive because their percentages
are associated with the concentration of serum anti-
PLA2R antibodies and they actively produce anti-
PLA2R antibodies when expanded ex vivo.
Despite increasing evidence that the depletion of
circulating B cells with anti-CD20 antibodies reduces
autoantibody levels,35 proteinuria,35,36 and histologic
lesions,37 little evidence is available regarding the role of
these cells in the pathogenesis of MN. The current
paradigm postulates that B cells play a pathogenic role
mainly as precursors of plasmablasts and plasma cells
that possess the capacity of secreting antibodies.38 Most
plasma cells may survive in the bone marrow for years
in a quiescent form. However, peripheral antigen-
specific mBCs recirculate in the bloodstream and may
activate upon transient antigen reexposure38 and rapidly
switch into antibody-producing plasmablasts,38 which
have a much faster turnover.39 This could, at least in
part, explain the efficacy of CD20 targeting therapies
that have no direct effect on plasma cells.38,40,41 How-
ever, a fraction of MN patients do not respond to rit-
uximab treatment. Our finding that MN patients have
increased circulating plasma cells provides further
rationale for testing the safety and efficacy of depleting
plasma cells in MN patients with anti–PLA2R-specific
antibodies (ClinicalTrials.gov identifier: NCT04145440).
Consistent with this hypothesis, others19 have shown
abnormalities in the percentages of circulating B-cell
subsets of patients with MN compared with health
controls. Although our data support this finding, we
showed that many of the immunologic differences be-
tween MN patients and healthy controls were not
characteristic of MN, but they were shared between MN
and individuals with nonimmunologic CKD. Therefore,
changes in the overall B-cell pool may represent a feature
of chronic renal disease regardless of the initial etiology.
In our study, circulating plasma cells were the
subset that was most altered in MN patients. Increased
percentages of circulating plasma cells might be caused
by rapid generation of these cells or prolonged sur-
vival. In addition, disturbances in homing behavior or
B-cell trafficking are possible causes of the observed
expansion of this cell population in the peripheral
blood of patients with active disease.42 The finding that
the percentages of circulating plasma cells were
significantly associated with the levels of serum anti-
PLA2R autoantibodies strongly suggests that a frac-
tion of these circulating cells are autoreactive. In order
to gain further insight about the role of autoreactive B
cells in MN patients, we used novel technologies to
track circulating autoreactive B cells in an antigen-
specific manner. Here, we document that MN patients
with serum anti-PLA2R antibodies at the time of the
clinical flare do have circulating mBCs capable ofKidney International Reports (2020) 5, 1764–1776converting into PLA2R-specific IgG-producing plas-
mablasts. Interestingly, 1 patient with clinical remis-
sion but persistent anti–PLA2R-specific antibodies in
the serum had no detectable circulating PLA2R-specific
plasma cell frequencies, suggesting that the disap-
pearance of these autoreactive cells from the circulation
might anticipate clinical remission.
We observed increased levels of TNF-a in MN pa-
tients. The role of TNF-a in the pathogenesis of MN has
been reported in previous studies,43–45 and there is a
reported association between a polymorphism in the
TNF-a gene and susceptibility to MN.46 Because acti-
vated B cells and plasma cells produce TNF-a,47,48 it is
possible to speculate that increased levels of TNF-a are
related to increased B-cell activation in MN patients.
To the best of our knowledge, our study is the first
reporting increased BREG in patients with primary MN.
Although we acknowledge that our analysis did not
test the function of these cells, our data are consistent
with those reported in kidney transplant recipients,49
where increased regulatory cells are thought to repre-
sent a counterregulatory mechanism to control allor-
eactive immunity. Increased regulatory cells may
represent a reaction to control effector B- and T-cell
responses and, consistent with this hypothesis, some of
the B cells that are found in the renal interstitium of
MN patients50 could have a regulatory function. The
results presented here may form the basis for future
studies aimed at understanding their pathogenic role.
Previous studies showed a reduction in total
CD4þCD25þCD127low TREG in MN patients compared
with healthy controls. Our study did not confirm this
finding, but it showed that CCR4þCD45RA-TREG, a
subset previously associated with increased regulatory
function,51 was significantly lower in MN patients than
in controls. Overall, this supports the idea that, similar
to other autoimmune diseases,52,53 MN is associated
with impaired TREG function, instead of TREG number.
PhIP-Seq uses oligonucleotide library synthesis to
encode proteomic-scale peptide libraries for display on
bacteriophage. These libraries are then immunoprecipi-
tated using individual’s serum antibodies for subse-
quent analysis by high-throughput DNA sequencing.
The methodology has been used to identify novel self-
antigens associated with autoimmune disease and
exposure to human viruses. Herein, PhIP-Seq analysis
showed that no single autoantigen or antiviral specificity
segregates MN from CKD or healthy controls. The fact
that the technique does not account for the protein 3-
dimensional structure may partially account for this
negative result. However, it is reasonable to argue that
abnormalities in the circulating B-cell and plasma cell
compartments in MN patients are largely limited to the
anti-PLA2R autoreactive clones.1773
TRANSLATIONAL RESEARCH C Cantarelli et al.: Plasma Cells in Membranous NephropathyOur article has numerous strengths. First, we per-
formed an extensive immune phenotypic characteriza-
tion of B- and T-cell subsets, including markers and
cell populations that have not been previously
considered. Second, the study design included a large
number of samples from MN patients and both healthy
and CKD controls, which allowed us to apply statistical
tools adequate for multidimensional and highly corre-
lated data in order to detect subsets that were likely
unique to MN patients. Finally, we developed novel
assays to evaluate the function of circulating autor-
eactive antibody-producing cells specific against the
PLA2R antigen. The data obtained by using these new
immune tools may significantly help in a better un-
derstanding of the pathogenic role of the autoimmune B
cells and plasma cells in patients with MN as well as
their value in predicting response to therapy and early
detecting relapses, before an increase in autoanti-
bodies.54 Importantly, the number of autoreactive B
cells may also identify MN patients who would benefit
the most from higher doses of rituximab.55
The main limitation of the present study is the lack
of serial samples. Although the correlation between
plasma cells and anti-PLA2R antibody levels supports a
relationship between the percentages of these cells and
disease activity, prospective studies are needed to
better define the association between spontaneous or
treatment-induced disease remission.
Altogether, our study newly documents that the
main immunologic abnormalities in MN patients rely in
increased circulating plasma cells and BREG. This pool
of plasma cells contains autoantibody-producing cells.
Our data provide the background for studies testing
the hypothesis that targeting these cells ameliorates
disease severity (ClinicalTrials.gov identifier:
NCT04145440).56,57DISCLOSURE
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Figure S1. The correlation plot of the 52 cell subsets in 71
patients with complete data (30 with membranous
nephropathy, 31 with chronic kidney disease, and 10
health controls).
Figure S2. Variable importance (VIMP) from random forest
analysis. A large VIMP value for a cell subset indicates that
misspecification of that variable decreases ability in the
forest in distinguishing between subjects with
membranous nephropathy and the other 2 conditions
based on the cell subsets. VIMP close to 0 indicates that
the cell subset contributes nothing to distinguishing
between groups, and negative values indicate that the
ability to distinguish between groups improves when the
cell subset is misdefined. In the latter case, we assume
noise is more informative than the true cell subset. As
such, if we ignore cell subsets with negative and near
zero values of VIMP, we are left mostly with B-cell
subsets. Among them, plasma cells and regulatory B
cells (Breg) had the largest VIMP.
Figure S3. Least absolute shrinkage and selection operator
(LASSO) for variable selection. Standardized coefficient
estimates as a function of the tuning parameter, which
“shrinks" the coefficient toward 0 as its value (on x-axis)
gets larger; by setting some coefficient to 0, the tuning
parameter determines which variables the LASSO will
eventually exclude. Plasma cells and regulatory B cells
(BREG) had the largest standardized coefficients and
would have been selected (along with B cells) as the onlyKidney International Reports (2020) 5, 1764–1776
C Cantarelli et al.: Diabetic Nephropathy TRANSLATIONAL RESEARCHsignificant cell subsets had the tuning parameter been set
to the level of the vertical dotted line.
Figure S4. Interferon (IFN)-gþ, interleukin (IL)-4þ, and IL-
17þ CD4þ T-cell subsets in membranous nephropathy
(MN), chronic kidney disease (CKD) patients, and healthy
controls (HC). Data are presented as mean  standard
deviation. Each dot represents the value for a single
patient.
Figure S5. Serum levels of tumor necrosis factor-a (TNF-a).
Serum levels of TNF-a in patients with membranous
nephropathy (MN) and healthy controls (HC). Data are
presented as mean  standard deviation. Each dot
represents the value for a single patient. P < 0.05 by
unpaired t test and Holm-Bonferroni adjustment for mul-
tiple comparisons.
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